JP2012502962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502962A5 JP2012502962A5 JP2011527342A JP2011527342A JP2012502962A5 JP 2012502962 A5 JP2012502962 A5 JP 2012502962A5 JP 2011527342 A JP2011527342 A JP 2011527342A JP 2011527342 A JP2011527342 A JP 2011527342A JP 2012502962 A5 JP2012502962 A5 JP 2012502962A5
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- pharmaceutical composition
- composition according
- condition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 10
- 229940116269 uric acid Drugs 0.000 claims 10
- 108010092464 Urate Oxidase Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 229940005267 urate oxidase Drugs 0.000 claims 4
- 102000007990 Organic Anion Transporters Human genes 0.000 claims 3
- 108010089503 Organic Anion Transporters Proteins 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 230000029142 excretion Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- LLMGYOJUHDRDFJ-UHFFFAOYSA-N 5-(dimethylamino)-9-methyl-2-propylpyrazolo[1,2-a][1,2,4]benzotriazine-1,3-dione;dihydrate Chemical compound O.O.CC1=CC=C2N=C(N(C)C)N3C(=O)C(CCC)C(=O)N3C2=C1 LLMGYOJUHDRDFJ-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims 1
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 claims 1
- 108010093894 Xanthine oxidase Proteins 0.000 claims 1
- 102100033220 Xanthine oxidase Human genes 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims 1
- 229960001671 azapropazone Drugs 0.000 claims 1
- 229960002529 benzbromarone Drugs 0.000 claims 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000007881 chronic fibrosis Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960003081 probenecid Drugs 0.000 claims 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical group CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 1
- 108010084837 rasburicase Proteins 0.000 claims 1
- 229960000424 rasburicase Drugs 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 229960003329 sulfinpyrazone Drugs 0.000 claims 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 claims 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305565A EP2165705A1 (en) | 2008-09-18 | 2008-09-18 | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
| EP08305565.7 | 2008-09-18 | ||
| PCT/EP2009/062159 WO2010031859A1 (en) | 2008-09-18 | 2009-09-18 | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502962A JP2012502962A (ja) | 2012-02-02 |
| JP2012502962A5 true JP2012502962A5 (https=) | 2012-11-01 |
Family
ID=40329393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527342A Pending JP2012502962A (ja) | 2008-09-18 | 2009-09-18 | 肺の炎症および線維症の予防および／または治療のための尿酸レベルを低下させることができる化合物の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8569017B2 (https=) |
| EP (2) | EP2165705A1 (https=) |
| JP (1) | JP2012502962A (https=) |
| CA (1) | CA2737392A1 (https=) |
| WO (1) | WO2010031859A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102133290B1 (ko) * | 2018-10-23 | 2020-07-13 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
| CN114746546B (zh) * | 2019-10-29 | 2024-09-03 | 西湖生物医药科技(杭州)有限公司 | 工程化红细胞用于治疗痛风和高尿酸血症 |
| US12577211B2 (en) * | 2020-06-29 | 2026-03-17 | Bacainn Biotherapeutics, Ltd. | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
| CN115039737B (zh) * | 2021-08-09 | 2023-07-25 | 北京中医药大学 | 一种建立尿酸盐肾沉积动物模型的方法 |
| KR20230050232A (ko) | 2021-10-07 | 2023-04-14 | 주식회사 이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028660B1 (de) | 1979-11-10 | 1985-10-23 | Siegfried Aktiengesellschaft | Xanthinoxydasehemmer und Verwendung von Benztriazinderivaten |
| US5021448A (en) | 1990-02-22 | 1991-06-04 | Ciba-Geigy Corporation | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist |
| ATE498409T1 (de) | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| CN101092400A (zh) | 2001-11-16 | 2007-12-26 | 日本化学医药株式会社 | 黄嘌呤氧化酶抑制剂 |
| CA2462132C (en) | 2002-01-28 | 2010-08-10 | Fuji Yakuhin Co., Ltd. | 1,2,4-triazole compounds |
| WO2005030138A2 (en) * | 2003-09-26 | 2005-04-07 | Webb Waring Institute | Methods of modulating inflammatory reactions by modulating xanthine oxidoreductase activity |
| WO2007077042A1 (en) * | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
| US8026382B2 (en) * | 2007-05-18 | 2011-09-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
| AU2008259768B2 (en) | 2007-06-05 | 2013-08-29 | Paka Pulmonary Pharmaceuticals, Inc. | Compositions for delivering medicaments into the lungs, uses thereof |
-
2008
- 2008-09-18 EP EP08305565A patent/EP2165705A1/en not_active Withdrawn
-
2009
- 2009-09-18 WO PCT/EP2009/062159 patent/WO2010031859A1/en not_active Ceased
- 2009-09-18 US US13/119,363 patent/US8569017B2/en not_active Expired - Fee Related
- 2009-09-18 EP EP09783212A patent/EP2344149A1/en not_active Withdrawn
- 2009-09-18 CA CA2737392A patent/CA2737392A1/en not_active Abandoned
- 2009-09-18 JP JP2011527342A patent/JP2012502962A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Kuraishy et al. | Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals | |
| Li et al. | Beclin 1/Bcl-2 complex-dependent autophagy activity modulates renal susceptibility to ischemia-reperfusion injury and mediates renoprotection by Klotho | |
| Ryter et al. | Autophagy: a lysosome-dependent process with implications in cellular redox homeostasis and human disease | |
| Ghavami et al. | Autophagy and the unfolded protein response promote profibrotic effects of TGF-β1 in human lung fibroblasts | |
| Aoyagi et al. | Cardiac mTOR protects the heart against ischemia-reperfusion injury | |
| JP2012502962A5 (https=) | ||
| Meloche et al. | Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension | |
| Sellers et al. | Inhibition of Marfan Syndrome aortic root dilation by losartan: Role of angiotensin II receptor type 1–independent activation of endothelial function | |
| CN110404073B (zh) | 治疗乙型肝炎病毒感染的方法和药物组合物 | |
| Collins et al. | Stromal interaction molecule 1 is essential for normal cardiac homeostasis through modulation of ER and mitochondrial function | |
| Andersson et al. | Revisiting the role of the mast cell in asthma | |
| JP2021050218A (ja) | チロシンキナーゼ阻害剤を用いる組成物および方法 | |
| JP6993318B2 (ja) | Ｂ型肝炎ウイルス複製の調節 | |
| JPWO2002064169A1 (ja) | Ａｏｐ−１遺伝子又はａｏｐ−１の発現減少を伴う疾患の治療方法及び当該疾患治療薬 | |
| US20220280484A1 (en) | Novel use | |
| JP2016520130A (ja) | 心臓疾患における新規治療戦略としてのｂｅｔ阻害 | |
| ES2897712T3 (es) | Procedimientos para seleccionar inhibidores selectivos de fosfatasa y no selectivos de fosfatasa | |
| JP2014532726A5 (https=) | ||
| JP2013539747A5 (https=) | ||
| Karakiulakis et al. | Muscarinic receptors and their antagonists in COPD: anti‐inflammatory and antiremodeling effects | |
| AU2016396401A1 (en) | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | |
| Zhang et al. | CIRP attenuates acute kidney injury after hypothermic cardiovascular surgery by inhibiting PHD3/HIF-1α-mediated ROS-TGF-β1/p38 MAPK activation and mitochondrial apoptotic pathways | |
| CN116966300A (zh) | Mcm8与相关信号通路物质作为疾病的诊疗靶点及其应用 | |
| Liu et al. | Downregulated microRNA‑133a induces HUVECs injury: Potential role of the (pro) renin receptor in angiotensin II‑dependent hypertension | |
| JPWO2012020821A1 (ja) | 非アルコール性脂肪肝炎の予防または治療剤 |